Stock Events

Stock Events

Exelixis 

$58.95
226
-$0.18-0.3% 19:18 Today

Statistics

Day High
59.24
Day Low
58.46
52W High
59.72
52W Low
33.76
Volume
16,687
Avg. Volume
-
Mkt Cap
14.61B
P/E Ratio
18.71
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
0.36
0.55
0.75
0.94
Expected EPS
0.88743
Actual EPS
N/A

Financials

33.73%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
2.32BRevenue
782.57MNet Income

Analyst Ratings

51.60Average Price Target
The highest estimate is 56.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
20%
Hold
80%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EXEL. It's not an investment recommendation.
NVIDIA
54
NVDA
Microsoft
49
MSFT
Amazon
45
AMZN
Apple
44
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb competes in the oncology space with a broad portfolio of cancer treatments, overlapping with Exelixis's focus on cancer therapeutics.
Merck
MRK
Mkt Cap366B
Merck is a leading competitor in the oncology market, particularly with its blockbuster cancer drug Keytruda, which competes in indications similar to those of Exelixis's products.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diverse oncology portfolio that includes treatments for various types of cancer, directly competing with Exelixis's cancer therapies.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in the same therapeutic areas as Exelixis, with a strong focus on oncology and a pipeline of cancer drugs that compete with Exelixis's offerings.
Roche
RHHBY
Mkt Cap334.28B
Roche, through its Genentech division, develops and markets oncology drugs that compete with Exelixis's cancer treatments, particularly in the areas of targeted therapy and immunotherapy.
Novartis
NVS
Mkt Cap292.35B
Novartis competes with Exelixis in the oncology sector, offering a range of cancer treatments that overlap with Exelixis's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its acquisition of Kite Pharma, has expanded its oncology portfolio, competing with Exelixis in the cancer treatment market.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a presence in the oncology market with treatments that compete against Exelixis's cancer therapies, including targeted therapies and biologics.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes in the oncology space with a focus on innovative cancer treatments, including immunotherapies that rival Exelixis's products.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation has a portfolio of oncology products that directly compete with Exelixis's cancer therapies, particularly in the areas of targeted therapy and immunotherapy.

About

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Show more...
CEO
Michael Morrissey
Employees
1077
Country
United States
ISIN
US30161Q1040
WKN
000936718

Listings

MI
IT
1EXEL.MI
STU
DE
EX9.STU
F
DE
EX9.F
MU
DE
EX9.MU

0 Comments

Share your thoughts

FAQ

What is Exelixis stock price today?▼
The current price of EXEL is $58.95 USD — it has decreased by -0.3% in the past 24 hours. Watch Exelixis stock price performance more closely on the chart.
What is Exelixis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Exelixis stocks are traded under the ticker EXEL.
Is Exelixis stock price growing?▼
EXEL stock has risen by +8.27% compared to the previous week, the month change is a +5.28% rise, over the last year Exelixis has showed a +57.72% increase.
What is Exelixis market cap?▼
Today Exelixis has the market capitalization of 14.61B
When is the next Exelixis earnings date?▼
Exelixis is going to release the next earnings report on November 03, 2026.
What were Exelixis earnings last quarter?▼
EXEL earnings for the last quarter are 0.91 USD per share, whereas the estimation was 0.85 USD resulting in a +6.63% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Exelixis revenue for the last year?▼
Exelixis revenue for the last year amounts to 2.32B USD.
What is Exelixis net income for the last year?▼
EXEL net income for the last year is 782.57M USD.
How many employees does Exelixis have?▼
As of September 04, 2026, the company has 1,077 employees.
In which sector is Exelixis located?▼
Exelixis operates in the Health & Wellness sector.
When did Exelixis complete a stock split?▼
Exelixis has not had any recent stock splits.
Where is Exelixis headquartered?▼
Exelixis is headquartered in ALAMEDA, United States.